Amryt Pharma plc (AMYT) Income Statement Analysis

See more : VGP NV (0HM0.L) Income Statement Analysis – Financial Results

Complete financial analysis of Amryt Pharma plc (AMYT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amryt Pharma plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

Infotel SA (INF.PA) Income Statement Analysis – Financial Results
Standard Development Group Limited (1867.HK) Income Statement Analysis – Financial Results
American Clean Resources Group, Inc. (SMPR) Income Statement Analysis – Financial Results
New Pacific Metals Corp. (NUAG.TO) Income Statement Analysis – Financial Results
IS DongSeo Co., Ltd. (010780.KS) Income Statement Analysis – Financial Results

Amryt Pharma plc (AMYT)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://www.amrytpharma.com

About Amryt Pharma plc

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Metric	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	222.54M	182.61M	58.12M	16.53M	15.33M	1.42M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	106.12M	119.03M	42.00M	6.06M	6.45M	616.30K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	116.42M	63.58M	16.12M	10.47M	8.88M	804.55K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit Ratio	52.32%	34.82%	27.74%	63.35%	57.95%	56.62%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	37.73M	27.62M	15.83M	10.35M	12.67M	2.47M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	8.34M	4.73M	841.00K	17.57M	13.25M	4.25M	3.33M	2.93M	1.87M	275.37K	281.22K	1.72M	1.74M	3.05M	2.33M
Selling & Marketing	92.00M	76.67M	35.50M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	100.34M	81.40M	36.34M	17.57M	13.25M	4.25M	3.33M	2.93M	1.87M	275.37K	281.22K	1.72M	1.74M	3.05M	2.33M
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-80.83K	-47.51K	5.03K	11.50K
Operating Expenses	138.07M	109.02M	52.17M	27.92M	25.93M	6.95M	3.34M	2.93M	1.86M	275.37K	281.22K	281.82K	1.74M	3.05M	2.33M
Cost & Expenses	244.18M	228.05M	94.17M	33.98M	32.37M	7.57M	3.34M	2.93M	1.86M	275.37K	281.22K	281.82K	1.74M	3.05M	2.33M
Interest Income	5.00K	87.00K	92.00K	5.72K	6.00K	1.05K	185.00K	201.00K	319.07K	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	27.91M	19.57M	8.48M	1.78M	989.75K	127.26K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	50.74M	44.47M	12.63M	354.61K	310.72K	204.03K	6.00K	6.00K	4.56K	0.00	99.63K	147.69K	144.69K	224.23K	161.09K
EBITDA	29.10M	-977.00K	-23.42M	-17.09M	-16.73M	-5.94M	33.26M	-3.10M	-1.27M	-275.37K	-281.22K	-281.82K	-1.60M	-2.83M	-2.17M
EBITDA Ratio	13.08%	-0.54%	-40.29%	-103.36%	-109.16%	-418.28%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-21.64M	-45.44M	-36.04M	-17.44M	-17.04M	-8.08M	-39.93M	-2.93M	-3.51M	-275.37K	-281.22K	-281.82K	-459.87K	-3.28M	-2.43M
Operating Income Ratio	-9.72%	-24.89%	-62.01%	-105.51%	-111.18%	-568.69%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-8.17M	-60.42M	-30.72M	-12.00M	-14.31M	-127.26K	189.00K	-36.81M	376.00K	-1.84M	-5.85K	0.00	-63.03K	7.94K	14.28K
Income Before Tax	-29.81M	-105.86M	-66.76M	-29.45M	-31.36M	-8.21M	-39.74M	-2.56M	-2.12M	-275.37K	-281.22K	-281.82K	-522.90K	-3.27M	-2.41M
Income Before Tax Ratio	-13.40%	-57.97%	-114.86%	-178.09%	-204.54%	-577.65%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	-11.64M	-1.33M	-1.23M	41.18K	14.31M	1.93M	73.18M	-175.00K	2.23M	550.74K	2.68M	1.51K	-25.79K	226.22K	101.27K
Net Income	-18.17M	-104.53M	-65.54M	-29.49M	-45.67M	-8.21M	-39.74M	-2.56M	-2.12M	-826.12K	-3.06M	-123.58K	-497.11K	-3.27M	-2.41M
Net Income Ratio	-8.17%	-57.24%	-112.75%	-178.34%	-297.89%	-577.65%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-0.39	-2.92	-4.32	-3.22	-6.14	-1.51	-3.45	-0.26	-0.33	-0.08	-0.30	-0.01	-0.05	-0.42	0.00
EPS Diluted	-0.37	-2.92	-4.32	-3.22	-6.14	-1.51	-3.45	-0.26	-0.33	-0.08	-0.30	-0.01	-0.05	-0.42	0.00
Weighted Avg Shares Out	47.17M	35.76M	15.17M	9.16M	7.44M	5.44M	11.51M	9.81M	6.47M	10.12M	10.12M	10.12M	9.59M	7.87M	0.00
Weighted Avg Shares Out (Dil)	49.40M	35.76M	15.17M	9.16M	7.44M	5.44M	11.51M	9.81M	6.47M	10.12M	10.12M	10.12M	9.59M	7.87M	0.00

Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q3 Loss, Tops Revenue Estimates

November 3, 2021zacks.com

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 66.67% and 7.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Amryt Pharma third-quarter revenue up over 14% on soaring metreleptin sales

November 3, 2021proactiveinvestors.co.uk

Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT) announced revenue growth of 14.6% for the third quarter after sales of its lipodystrophy treatment metreleptin soared 21.5%. Revenue rose to US$56.5mln in the three months to end-September from US$49.3mln in the same period last...

Amryt Pharma backs EB awareness week

October 22, 2021proactiveinvestors.co.uk

Amryt Pharma PLC has announced its support for Global Epidermolysis Bullosa (EB) Awareness Week, which is taking place October 25 - 31, 2021. Joe Wiley, Amryt's chief executive, said: "Epidermolysis Bullosa is a very distressing condition which severely impacts the lives of those...

Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3

October 20, 2021globenewswire.com

A mryt to Report Q 3 202 1 Results and Host Conference Call & Webcast on November 3

Amryt Pharma extends patent protection on key products

October 19, 2021proactiveinvestors.co.uk

Amryt has extended the patents on its lead development candidate, Oleogel-S10 and its recently acquired commercial product, Mycapssa. For Oleogel-S10, a treatment for skin condition EB, the US patent office has issued a new formulation patent to Amryt, which will...

Amryt Announces New Patents for Oleogel-S10 and Mycapssa®

October 19, 2021globenewswire.com

Amryt Announces New Patents for Oleogel-S10 and Mycapssa®

Amryt Pharma impresses broker at Capital Markets Day

September 14, 2021proactiveinvestors.co.uk

Amryt Pharma has had its price target of US$40 and 'buy' rating reiterated by Canaccord after the company hosted a virtual capital markets day. Opinion leaders spoke on the near-term growth opportunities with Filsuvez in epidermolysis bullosa (EB) and Mycapssa in acromegaly,...

Amryt Pharma raises sales forecast again as acquisition makes strong start

September 13, 2021proactiveinvestors.co.uk

Amryt Pharma has raised its full-year 2021 revenue guidance due to a strong performance from recent acquisition of Chiasma and its own commercial products. Revenues are now expected in a range of US220mln - $225mln compared to previous guidance of US$210mln-...